Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2006 Mar;61(3):262-74.
doi: 10.1111/j.1365-2125.2005.02568.x.

Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy

Ulrike Resch  1 , Franz Tatzber, Alexandra Budinsky, Helmut Sinzinger
Affiliations
Randomized Controlled Trial

Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy

Ulrike Resch et al. Br J Clin Pharmacol. 2006 Mar.

Abstract

Aims: To examine the effect of 24 weeks' rosuvastatin treatment on oxidative stress and changes in immune response to oxidized low-density lipoprotein (LDL).

Methods: This was an open-label study of patients in Austria receiving 10 or 40 mg rosuvastatin daily alternately during 12 and 24 weeks. Circulating concentrations of antibodies to malondialdehyde-oxidized LDL (MDA-LDL), both IgG and IgM type, to copper-oxidized LDL (Cu-OxLDL-IgG), concentrations of oxidized LDL complexed to IgG (OxLDL-IC) and markers of oxidative stress and systemic inflammation in subjects with plasma LDL cholesterol concentrations between 130 mg dl-1 and 250 mg dl-1 and triglycerides<or=400 mg dl-1 were determined.

Results: During statin therapy, plasma endogenous peroxides (POX-ACT) concentrations and peroxidase activity were significantly decreased, associated with a modest increase in total antioxidant capacity (TAC). Antibody titres to MDA-LDL-IgM, Cu-OxLDL-IgG and OxLDL-IC decreased, whereas MDA-LDL-IgG concentrations were increased after therapy. These changes were dose- and LDL-independent. POX-ACT concentrations were significantly positively correlated with inflammation markers before and after therapy and inversely with high-density lipoprotein-cholesterol concentrations after therapy.

Conclusion: This study provides in vivo evidence that rosuvastatin significantly reduces oxidative stress and has immunomodulatory properties in a dose- and LDL-independent manner.

PubMed Disclaimer

References

    1. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of CHD using risk factor categories. Circulation. 1998;97:1837–47. - PubMed
    1. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868–74. - PubMed
    1. Stadtman ER, Berlett BS. Reactive oxygen-mediated protein-oxidation in ageing and disease. Drug Metab Rev. 1998;30:225–43. - PubMed
    1. Steinbrecher UP, Eisher M, Witztum JL, Curtiss LK. Immunogenicity of homologous low density lipoprotein after methylation, ethylation, acetylation or carbamylation: generation of antibodies specific for derivatized lysine. J Lipid Res. 1984;25:1109–16. - PubMed
    1. Steinbrecher UP. Oxidation of human low-density lipoprotein results in derivatization of lysine residues of apolipoprotein B by lipid peroxide decomposition products. J Biol Chem. 1987;262:3603–8. - PubMed

Publication types

MeSH terms